Novel agents for myelodysplastic syndromes

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders with limited therapeutic options until recently.
• Recent advancements have led to two new US Food and Drug Administration (FDA) drug approvals for MDS treatment.
• Luspatercept-aamt and decitabine/cedazuridine are novel agents targeting different pathways in MDS management.

Purpose of the Study:

• To review the pharmacology, pharmacokinetics, clinical trials, and therapeutic use of luspatercept-aamt and decitabine/cedazuridine.
• To discuss adverse effects, clinical controversies, and upcoming trials for these novel MDS agents.
• To provide a comprehensive overview of recent advances in MDS treatment.

Main Methods:

• Primary data from published studies and package inserts for luspatercept-aamt and decitabine/cedazuridine.
• Secondary data from National Comprehensive Cancer Network (NCCN) guidelines and PubMed searches using relevant keywords.
• Keywords included: luspatercept-aamt, myelodysplastic syndromes, decitabine, cedazuridine, hypomethylating agent, ASTX727.

Main Results:

• Luspatercept-aamt, an erythroid maturation agent, demonstrated efficacy in the MEDALIST trial for transfusion independence in patients with lower-risk MDS.
• Decitabine/cedazuridine, a hypomethylating agent, showed efficacy and a similar safety profile to IV decitabine in the ASCERTAIN study for intermediate/high-risk MDS.
• Both agents met primary endpoints in their respective phase III trials, indicating clinical benefit.

Conclusions:

• Luspatercept-aamt and decitabine/cedazuridine represent significant therapeutic advancements in myelodysplastic syndromes.
• These novel agents provide clinical benefit to specific patient populations within the MDS spectrum.
• The review covers key aspects of these drugs, aiding clinicians in their use.